Fusarium keratitis in Brazil: Genotyping, in vitro susceptibilities, and clinical outcomes

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1693-1701

  Oechsler, Rafael A ^a   Yamanaka, Tiago M ^a   Bispo, Paulo J M ^a   Sartori, Juliana ^a   Yu, Maria Cecilia Zorat ^a   Melo, Analy Salles A ^a   Miller, Darlene ^b   Hofling Lima, Ana Luisa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal; Clinical outcome; Fusarium species; Genotyping; Keratitis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE; KETOCONAZOLE; NATAMYCIN; PIMARICINA; UNCLASSIFIED DRUG; VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BRAZIL; BROTH DILUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA PERFORATION; FEMALE; FUNGUS ISOLATION; FUSARIUM KERATITIS; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; INJURY; KERATOMYCOSIS; KERATOPLASTY; MALE; MEDICAL RECORD; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; VISUAL ACUITY;

EID: 84883307326     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S40063     Document Type: Article

References (38)

1. Furlanetto RL, Andreo EG, Finotti IG, etal. Epidemiology and etiologic diagnosis of infectious keratitis in Uberlandia, Brazil. Eur J Ophthalmol. 2010;20:498-503.
2. Cariello AJ, Passos RM, Yu MC, etal. Microbial keratitis at a referral center in Brazil. Int Ophthalmol. 2011;31:197-204.
3. Chowdhary A, Singh K. Spectrum of fungal keratitis in North India. Cornea. 2005;24:8-15.
4. Xie L, Zhong W, Shi W, et al. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113:1943-1948.
5. Ibrahim MM, Vanini R, Ibrahim FM, etal. Epidemiologic aspects and clinical outcome of fungal keratitis in southeastern Brazil. Eur J Ophthalmol. 2009;19:355-361.
6. Hofling-Lima AL, Forseto A, Duprat JP, etal. Laboratory study of the mycotic infectious eye diseases and factors associated with keratitis. Arq Bras Oftalmol. 2005;68:21-27.
7. Godoy P, Cano J, Gene J, etal. Genotyping of 44 isolates of Fusarium solani, the main agent of fungal keratitis in Brazil. J Clin Microbiol. 2004;42:4494-4497.
8. O'Donnell K, Sarver BA, Brandt M, etal. Phylogenetic diversity and microsphere array-based genotyping of human pathogenic Fusaria, including isolates from the multistate contact lens-associated US keratitis outbreaks of 2005 and 2006. J Clin Microbiol. 2007;45: 2235-2248.
9. Oechsler RA, Feilmeier MR, Ledee D, etal. Utility of molecular sequence analysis of the ITS rRNA region for identification of Fusarium spp. from ocular sources. Invest Ophthalmol Vis Sci. 2009;50: 2230-2236.
10. Chen A, Prajna L, Srinivasan M, etal. Does in vitro susceptibility predict clinical outcome in bacterial keratitis? Am J Ophthalmol. 2008;145:409-412.
11. Lalitha P, Srinivasan M, Manikandan P, etal. Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis. Clin Infect Dis. 2012;54:1381-1387.
12. Kaye S, Tuft S, Neal T, etal. Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51:362-368.
13. Pradhan L, Sharma S, Nalamada S, etal. Natamycin in the treatment of keratomycosis: correlation of treatment outcome and in vitro susceptibility of fungal isolates. Indian J Ophthalmol. 2011;59:512-514.
14. Lalitha P, Prajna NV, Oldenburg CE, etal. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial. Cornea. 2012;31:662-667.
15. Shapiro BL, Lalitha P, Loh AR, etal. Susceptibility testing and clinical outcome in fungal keratitis. Br J Ophthalmol. 2010;94:384-385.
16. Scott IU, Schein OD, West S, etal. Functional status and quality of life measurement among ophthalmic patients. Arch Ophthalmol. 1994;112: 329-335.
17. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved Standard M38-A2, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
18. Tamura K, Dudley J, Nei M, etal. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596-1599.
19. Posada D. jModelTest: phylogenetic model averaging. Mol Biol Evol. 2008;25:1253-1256.
20. Huelsenbeck JP, Ronquist F. MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics. 2001;17:754-755.
21. Maddison DR. Testing monophyly of a group of beetles. Study 1in Mesquite: a modular system for evolutionary analysis, version 1.04. 2004. Available from: http://mesquiteproject.org/mesquite2.0/Mesquite_Folder/docs/mesquite/studies/study001/index.html. Accessed June 19, 2013.
22. Lalitha P, Vijaykumar R, Prajna NV, etal. In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder. J Clin Microbiol. 2008;46:3477-3478.
23. Wong TY, Ng TP, Fong KS, etal. Risk factors and clinical outcomes between fungal and bacterial keratitis: a comparative study. CLAO J. 1997;23:275-281.
24. Oechsler RA, Feilmeier MR, Miller D, etal. Fusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes. Cornea. 2013;32:667-673.
25. Mukherjee PK, Chandra J, Yu C, etal. Characterization of Fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. Invest Ophthalmol Vis Sci. 2012;53: 4450-4457.
26. Alfonso EC, Cantu-Dibildox J, Munir WM, etal. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol. 2006;124:941-947.
27. Iyer SA, Tuli SS, Wagoner RC. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens. 2006;32:267-271.
28. Ritterband DC, Seedor JA, Shah MK, etal. Fungal keratitis at the New York Eye and Ear Infirmary. Cornea. 2006;25:264-267.
29. Tanure MA, Cohen EJ, Sudesh S, etal. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea. 2000;19: 307-312.
30. Keay LJ, Gower EW, Iovieno A, etal. Clinical and microbiological characteristics of fungal keratitis in the United States, 2001-2007: a multicenter study. Ophthalmology. 2011;118:920-926.
31. Rautaraya B, Sharma S, Kar S, etal. Diagnosis and treatment outcome of mycotic keratitis at a tertiary eye care center in eastern India. BMC Ophthalmol. 2011;11:39-46.
32. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998;36: 198-202.
33. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001;150:101-115.
34. Marangon FB, Miller D, Giaconi JA, et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004;137:820-825.
35. Reuben A, Anaissie E, Nelson PE, etal. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother. 1989;33: 1647-1649.
36. Tortorano AM, Prigitano A, Dho G, etal. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother. 2008;52:2683-2685.
37. Wang H, Xiao M, Kong F, etal. Accurate and practical identification of 20 Fusarium species by seven-locus sequence analysis and reverse line blot hybridization, and an in vitro antifungal susceptibility study. J Clin Microbiol. 2011;49:1890-1898.
38. O'Day DM, Head WS, Robinson RD, etal. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986;5:877-882.